Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insmed 'hopeful' over inhaled amikacin but share price continues nose dive

This article was originally published in Scrip

Executive Summary

Insmed said it is hopeful that it can resume the Phase III trial of its lead candidate Arikace (liposomal amikacin for inhalation) during the fourth quarter of the year, following a US FDA decision to place a clinical hold on the programme at the start of August. The agency based its decision on an initial review of the interim results of a long-term rat inhalation carcinogenicity study with Arikace, recently reported to the agency by Insmed.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel